Edesa Biotech, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| EDSA | CVM | MREO | ENTA | 6OP.F | HBP.TO | |
|---|---|---|---|---|---|---|
| Market cap | 29.32M | 24.27M | 48.40M | 310.19M | 42.99M | 70.27M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -0.2 | -13.1 | -4.5 | — | -8.4 |
| Price/book | 52.9 | 2.2 | 1.7 | 3.1 | 1.4 | 4.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +27.65% | −79.22% | −82.78% | −1.39% | −66.91% | −54.68% |
| Today | −4.82% | −2.13% | +4.16% | +2.70% | −2.85% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All EDSA news ›Edesa Biotech (NASDAQ:EDSA) Cut to Strong Sell at Wall Street Zen
Posted by Danessa Lincoln on Oct 20th, 2026 Wall Street Zen lowered shares of Edesa Biotech (NASDAQ:EDSA – Free Report) from a sell rating to a strong sell rating in a research report released on Saturday,Wall Street Zen reports. View Our…
Edesa Biotech gains FDA clearance to expand Phase 2 vitiligo trial
U.S. enrolment is expected in early 2027, with up to 80 adults testing EB06 against placebo and topline results due late that year. U.S. trial sites can join an ongoing vitiligo study after Edesa Biotech, Inc. NASDAQEDSA reported FDA…
More from 1 other outlet
Edesa Biotech Clears IND for Phase 2 EB06 Study in Vitiligo
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends. Edesa Biotech Clears IND for Phase 2 EB06 Study in Vitiligo About…
Edesa Biotech (NASDAQ:EDSA) Stock Falls 16.2% – Time to Sell?
Posted by Sarita Garza on Oct 13th, 2026 Edesa Biotech, Inc. (NASDAQ:EDSA – Get Free Report)’s stock price fell 16.2% on Monday. The company traded as low as $2.87 and last traded at $2.94. 81,606 shares traded hands during mid-day…
Edelteq plans another private placement to raise up to RM27 mil
KUALA LUMPUR (Oct 12): Just over a year after completing a private placement, Edelteq Holdings Bhd (KL:EDELTEQ) plans to undertake another private placement seeking to raise up to RM26.75 million. The company said it is to repay bank…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com2
- mugglehead.com1
- stocktitan.net1
- theedgemalaysia.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.